Age differences in endocannabinoid tone are ameliorated after recent cannabis use

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Endocannabinoid system (ECS) activity declines with age, potentially contributing to age-related conditions.
• Cannabis use is common among older adults for age-related issues, but its effects on the ECS across the lifespan are not well understood.

Purpose of the Study:

• To investigate how acute cannabis use affects endocannabinoid levels in adults of different age groups.
• To identify age-related differences in endocannabinoid levels at baseline and in response to cannabis.

Main Methods:

• Assayed levels of seven endocannabinoids (AEA, 2-AG, DEA, LEA, PEA, SEA, and OEA) in 142 adults (younger, midlife, older).
• Measurements were taken at baseline (pre-cannabis use) and after consuming either flower or edible cannabis.
• Statistical analysis examined age-group differences and changes in endocannabinoid levels post-cannabis use.

Main Results:

• Older adults had lower baseline levels of anandamide (AEA) and N-acylethanolamine-amide (DEA) compared to younger adults, and lower N-acylethanolamine (LEA) than midlife adults.
• Acute cannabis use significantly increased AEA, DEA, LEA, palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and oleamide (SEA) across all age groups.
• The increase in AEA and DEA was more pronounced in older adults, indicating an age-dependent acute response.

Conclusions:

• Cannabis consumption leads to widespread elevations in endocannabinoid levels, irrespective of age.
• Significant age-related variations exist in baseline endocannabinoid profiles and in the acute response to cannabis.
• These findings highlight the complex interplay between aging, the endocannabinoid system, and cannabis use.